Format

Send to

Choose Destination
Ann Hepatol. 2018 July - August ,;17(4):577-584. doi: 10.5604/01.3001.0012.0920.

Association Between Serum Hemoglobin Levels and Non Alcoholic Fatty Liver Disease in a Mexican Population.

Author information

1
ranslational Research Unit, Medica Sur Clinic & Foundation. Mexico City, Mexico.
2
Translational Research Unit, Medica Sur Clinic & Foundation. Mexico City, Mexico. Obesity and Digestive Diseases Unit, Medica Sur Clinic & Foundation. Mexico City, Mexico.
3
Obesity and Digestive Diseases Unit, Medica Sur Clinic & Foundation. Mexico City, Mexico.
4
CIDyT, Medica Sur Clinic & Foundation. Mexico City, Mexico.
5
Translational Research Unit, Medica Sur Clinic & Foundation. Mexico City, Mexico.

Abstract

INTRODUCTION AND AIM:

Nonalcoholic fatty liver disease (NAFLD) is closely associated with overweight and obesity, becoming one of the most prevalent hepatic diseases nowadays. Circulating hemoglobin (Hb) concentration is significantly higher in people with NAFLD, compared to healthy patients. While liver biopsy remains the gold standard for NAFLD diagnosis, it is not the best technique due to adverse events that may occur. Therefore it is important to find less invasive and more sensitive markers. This study aimed to determine the association of serum Hb levels in patients with steatosis and fibrosis as a noninvasive marker.

MATERIAL AND METHODS:

A 1,186 patient cross-sectional study nested in a randomized clinical trial (NCT01874249) was conducted. Patients were diagnosed by ultrasound for hepatic steatosis and fibroscan for fibrosis; blood test and anthropometric measurements were also assessed.

RESULTS:

Serum Hb increased proportionally related to the steatosis level, being significantly higher in patients with severe steatosis than in patients with moderate and mild steatosis.

CONCLUSION:

Patients with non-alcoholic fatty liver disease showed elevated levels of circulating Hb, evidence that suggests that Hb exerts a protective role, as it may act as an antioxidant and may counteract the adverse effects of this disease.

KEYWORDS:

Antioxidant; Hepatic disease; Non-invasive markers; Steatosis

PMID:
29893698
DOI:
10.5604/01.3001.0012.0920
Free full text

Supplemental Content

Full text links

Icon for IndexCopernicus
Loading ...
Support Center